Revolutionizing Human Health: CarboCode Secures $15M in Series C Funding

We're thrilled to announce that CarboCode has successfully raised $15 million in our latest funding round, marking a significant milestone in our journey to revolutionize human health through innovative biotechnological advancements. At CarboCode, our passion for enhancing human well-being drives us to tackle challenges considered impossible. With a dedicated team of elite scientists specializing in biotechnology, enzyme technology, and chemistry, our research center in Germany has been on a relentless quest to pioneer human sphingolipid production. This breakthrough is not just a scientific achievement; it represents a substantial leap forward in health technology. Our experienced development and manufacturing team in Portugal ensures that we can scale our production effectively and economically, making cutting-edge health solutions accessible to many. The funding will enable us to advance our research initiatives further while creating robust scientific and clinical evidence supporting the myriad benefits of human sphingolipids in critical areas such as skin health, infant nutrition, and cognitive functioning. With our first applications focused on skincare and infant nutrition, we're committed to transforming how these essential products can improve quality of life. This funding is not merely an investment in our company; it is an investment in the future of human health. We are excited to forge ahead, knowing that the impossible is quickly becoming our reality, and we won't stop there! Stay tuned for groundbreaking results that will set new standards in health and wellness.